Quantitative metastatic lymph node burden and survival in Merkel cell carcinoma - 11/01/21
Abstract |
Background |
Current lymph node (LN) staging for Merkel cell carcinoma (MCC) does not account for the number of metastatic LNs, which is a primary driver of survival in multiple cancers.
Objective |
To determine the impact of the number of metastatic LNs on survival in MCC.
Methods |
Patients with MCC undergoing surgery were identified from the National Cancer Database (NCDB). The association between metastatic LN number and survival was modeled with restricted cubic splines. A novel nodal classification system was derived by using recursive partitioning analysis. MCC patients undergoing surgery in the Surveillance, Epidemiology, and End Results (SEER) Program were used as validation cohort.
Results |
Among 3670 patients in the NCDB, increasing metastatic LN number was associated with decreased survival (P < .001). Mortality risk increased continuously with each additional positive LN when using multivariable, nonlinear modeling. According to a novel staging system derived via recursive partitioning analysis, the hazard ratio for death in multivariable regression compared with patients without LN involvement was 1.24 (P = .049), 2.08 (P < .001), 3.24 (P < .001), and 6.13 (P < .001) for the proposed N1a (1-3 metastatic LNs with microscopic detection), N1b (1-3 metastatic LNs with macroscopic detection), N2 (4-8 metastatic LNs), and N3 (≥9 metastatic LNs), respectively. This system was validated in the SEER cohort and showed improved concordance compared with the American Joint Committee on Cancer, Eighth Edition.
Limitations |
Retrospective design.
Conclusions |
Number of metastatic LNs is the dominant nodal factor driving survival in patients with MCC.
Il testo completo di questo articolo è disponibile in PDF.Key words : immunotherapy, lymph node staging, Merkel cell carcinoma, National Cancer Database, radiation, SEER
Abbreviations used : AJCC 8E, CI, ENE, HR, LN, MCC, NCDB, OS, RPA, SD, SEER
Mappa
| Funding sources: None. |
|
| Disclosure: Dr Faries is on the advisory board for Novartis, Regeneron, Pulse Bioscience, and Delcath Systems. Dr Zumsteg was on the external advisory board for the Scripps Proton Therapy Center and has consulted for EMD Serono. Dr Nguyen; Mr Luu; and Drs Lu, Hamid, Mallen-St. Clari, Gharavi, and Ho have no conflicts of interest to declare. |
|
| IRB approval status: Reviewed and deemed exempt by the Cedars-Sinai IRB. |
|
| Reprints not available from the authors. |
Vol 84 - N° 2
P. 312-320 - febbraio 2021 Ritorno al numero
Articolo precedente
- Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score–matched cohort study
- Maria C. Schneeweiss, Seoyoung C. Kim, Richard Wyss, Sebastian Schneeweiss, Joseph F. Merola
- Improved survival in women versus men with merkel cell carcinoma
- Moses Tam, Michael Luu, Christopher A. Barker, Nima M. Gharavi, Omid Hamid, Stephen L. Shiao, Anthony T. Nguyen, Diana J. Lu, Allen S. Ho, Zachary S. Zumsteg
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?